VUG240920P380000
- 13.80
- 0.000.00%
Vanguard Growth ETF Newsroom
As Fed Gears Up For Cuts, One Hedge Funder Is Focused On A Bigger Catalyst: Japan's Central Bank
Looking Into Eli Lilly's Recent Short Interest
10 Information Technology Stocks With Whale Alerts In Today's Session
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Stock Of The Day: Will Apple Bring The Market Down?
What's Going On With Micron's Stock?
How much impact does the rate cut by the Federal Reserve have on the "Seven Tech Giants"?
The rate cut may not bring as much help to the 'Seven Giants' as in the past.
Biggest Even Microsoft Buyback, New Retail Sales Go Against Prevailing Wisdom, Trump Crypto Project
Unpacking the Latest Options Trading Trends in Eli Lilly
Wedbush Spotlights DELL, NVDA, MSFT, and Others as Rate Cuts Should Support the AI Trend
Dan Niles Posts On X "Expectations for $AAPL Were for AI Features to Be Able to Drive ~10%+ Y/y Growth in iPhone Sales. If Accurate, Very Early Indications Are That Sales Are Down ~10%...." "The Staggered Rollout of the AI Feature Across Geographies,...
SCMP Earlier Reporter Online Retailers In China Have Reduced Prices iPhone 16 Prices Ahead Of Its Official Release
Qualcomm Analyst Sees Opportunity In 'Regaining Share With Samsung' After Apple Revenue Squeeze
Any Concerns Over iPhone Sales Are Just a Blip in the Road for Apple: Analysts
The supply chain is in disarray, leaving investors worried about the demand for iPhone 16.
Analysts including Ming-Chi Kuo of TF International, as well as analysts from Barclays, JPMorgan, and Bank of America, have all mentioned that early data shows the iPhone 16 Pro series is below expectations. This has led to a general decline in Apple's stock and related concept stocks on Monday. Kuo stated that one of the key factors for the decrease in demand for the iPhone 16 series is that the main selling point, Apple Intelligence, was not released with the iPhone 16.
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Dow Jumps Over 200 Points Ahead Of Fed Meeting: Investor Sentiment Improves But Fear & Greed Index Remains In 'Neutral' Zone
Microsoft Announces $60B Share Buyback Program, 10% Dividend Increase Amid Rising AI Investment And Restructuring
US stocks closing | The three major indexes have mixed gains and losses, with the Dow hitting a new high! The performance of technology stocks is divergent, with Intel up more than 6% and Apple down nearly 3%.
On the eve of the Federal Open Market Committee (FOMC) meeting, there was continued rotation in the U.S. stock market, with investors selling technology stocks and buying blue chip and small cap stocks.
Nasdaq 100 Falls As Apple Weighs On Chipmakers; Bonds Rise As Investors Eye 0.5% Rate Cut: What's Driving Markets Monday?